EDF Health

Greasing the skids: The Trump EPA is green-lighting dozens of new PFAS under TSCA

By / Published: July 28, 2020

Richard Denison, Ph.D., is a Lead Senior Scientist.

Under an obscure and opaque – and increasingly used – exemption that EPA provides under the Toxic Substances Control Act (TSCA), EPA has been quietly approving companies’ requests to introduce new poly- and per-fluorinated substances (PFAS) onto the market.  And it seems to be ramping up. [pullquote]Under this EPA the “low-volume exemption” (LVE) application process is proving to be very smooth sailing for getting new PFAS onto the market.[/pullquote]

PFAS is a class of chemicals that are showing up as environmental contaminants all over the country.  They are linked to large and growing list of adverse effects on human health.  These concerns have led to increased scrutiny about EPA’s actions to allow new PFAS to enter commerce.  EDF and others have raised concerns about a number of premanufacture notices (PMNs) companies have filed seeking approval to introduce new PFAS into commerce (see here and here); the PMN process is the standard way in which companies are to notify EPA of their intent to start manufacturing a new chemical.

But EPA has created other pathways to quickly get a chemical on the market, whereby companies can apply for an exemption from the PMN process.  As documented in this post, we have identified a whole lot of PFAS coming into EPA’s new chemicals program through exemptions, and most of them are getting quickly approved.  Worse yet, this side process is highly insulated from public scrutiny.  Read More »

Posted in Health policy, Health science, Industry influence, PFAS, Regulation, TSCA reform / Tagged , | Comments are closed

Former chemical industry official Beck, now at Trump White House, again interferes to weaken EPA action on dangerous chemicals: This time it’s PFAS

By / Published: April 20, 2020

Richard Denison, Ph.D., is a Lead Senior Scientist.

It was only in February that Reveal News’ Elizabeth Shogren exposed the Trump White House’s role in dramatically weakening the Environmental Protection Agency’s (EPA) draft risk evaluation for the solvent trichloroethylene (TCE), which is linked to fetal heart defects at low doses.  The White House’s 11th-hour intervention, led by former chemical industry official Dr. Nancy Beck, forced EPA to rely on a different health effect that would allow 500 times greater exposures to the ubiquitous toxic chemical.

There was every reason to expect this episode was not a one-off, given Beck’s other actions both while at EPA and once arriving at the White House.  Sure enough, last week Ellen Knickmeyer of the Associated Press exposed another such incident, this time involving a group of chemicals collectively known as “perfluoroalkyl and polyfluoroalkyl substances” or PFAS that are showing up as environmental contaminants all over the country.[pullquote]Beck’s first order of business was to compel her former colleagues at EPA to submit the proposed PFAS rule for White House review, which neither the Obama administration nor the Trump administration up to that point had deemed necessary.[/pullquote]

Knickmeyer reported on documents obtained by Senator Tom Carper of Delaware, ranking member of the Senate’s Environment and Public Works Committee, that detail Beck’s largely successful effort to scale back a rule EPA first proposed in 2015.  Called a Significant New Use Rule, or SNUR, it would require companies seeking to import products containing certain PFAS to notify EPA in advance, thereby allowing EPA to determine whether to allow the import and impose needed restrictions.  Sen. Carper made the documents public via a letter he sent to EPA Administrator Andrew Wheeler calling on EPA to finalize the original rule instead of the watered-down re-proposed rule EPA released for public comment in February.  Read More »

Posted in Health policy, Industry influence, PFAS, Regulation, TSCA reform / Tagged , , | Comments are closed

FDA scientists push back on an industry-funded analysis about bioaccumulation and toxicity of short-chain PFAS

By Tom Neltner, Senior Director, Safer Chemicals Initiative / Published: April 1, 2020

Tom Neltner, J.D., Chemicals Policy Director and Maricel Maffini, Ph.D., Consultant

Note to readers: As we all grapple with the grave global health challenge from COVID19, we want to acknowledge the essential services that professionals at the Food and Drug Administration (FDA) and in the food production, processing and retail industries provide in continuing to deliver food. In the meantime, we are continuing to work towards improved health protections – including reducing chemicals in food. We’ll plan to keep sharing developments that may be useful to you. In the meantime, please stay safe and healthy.

Last year, we reported on a sophisticated analysis performed by FDA’s scientists showing that 5:3 acid, a breakdown product of a short-chain PFAS known as 6:2 fluorotelomer (6:2 FTOH) was slow to be eliminated by the body. The authors concluded that the metabolite was an important biomarker for assessment of long-term exposure to 6:2 FTOH and showed potential bioaccumulative (aka biopersistence[1]) properties. The chemical 6:2 FTOH is a common starting substance in the manufacture of many PFAS polymers, including those used to greaseproof paper and paperboard. As a result, it is a major impurity in, and degradation product of, these polymers.

We are now reporting on two recent publications by the same group of FDA scientists (Kabadi et al.[2] and Rice et al.)[3] in which they not only confirmed their initial findings but also produced new evidence on the behavior of short-chain PFAS when they enter the body. The new evidence highlights:

  • Bioaccumulation: 6:2 FTOH is transformed by the body into several metabolites; one of them, called 5:3 acid, bioaccumulates, and the bioaccumulation is greater with lower exposure to 6:2 FTOH.
  • Toxicity: The toxicity of 6:2 FTOH is concerning and its risk to human health may have been significantly underestimated previously. Data on perfluorohexanoic acid (PFHxA), the industry’s proposed reference chemical for the short-chain PFAS class are not appropriate for assessing the potential health effects of 6:2 FTOH.

The FDA’s scientists reached these important conclusions after reviewing “recently received additional data on 6:2 FTOH and 5:3 acid” and more than a dozen reports on oral toxicity studies that “had been conducted and submitted by industry in support for food contact uses” of short-chain PFAS in addition to a study by the National Toxicology Program. They also called out flaws in industry-funded analyses that reached different conclusions.

Read More »

Posted in FDA, Health policy, Industry influence, PFAS / Tagged , | Comments are closed

FDA’s updated results for PFAS in food suggest progress but raise questions about its method

By Tom Neltner, Senior Director, Safer Chemicals Initiative / Published: November 20, 2019

Tom Neltner, J.D., Chemicals Policy Director and Maricel Maffini, Ph.D., Consultant

The Food and Drug Administration (FDA) recently released revised lab results from testing for 16 PFAS in food. Initial results of the testing were announced last June and gained wide attention because the levels of PFAS in certain foods were quite high. Surprisingly, the revised lab results show significantly fewer detections and, in the case of ground turkey and tilapia, concentrations of PFOS that are almost nine times lower than the values initially reported in June. In addition to the revised lab results, the agency also released a validated method for analyzing food for the substances and updated its PFAS webpage.

We were glad to see FDA’s ongoing work on PFAS and have already heard from commercial laboratories who are considering using the validated method as a potential new service to offer their customers. In analyzing the documentation that FDA provided,[1] we have concerns about the agency’s criteria to determine whether a sample had detectable levels of a PFAS. It appears unnecessarily restrictive and effectively underestimates the public’s exposure to PFAS. We are planning to meet with the agency to better understand their rationale for the criteria selection and its implications.

Read More »

Posted in FDA, Food, PFAS / Tagged , , | Read 1 Response

Think PFAS in food packaging are safe simply because FDA accepted their use? Think again.

By Tom Neltner, Senior Director, Safer Chemicals Initiative / Published: November 13, 2019

Tom Neltner, J.D., Chemicals Policy Director and Maricel Maffini, Ph.D., Consultant

[pullquote]

PFAS manufacturers’ claims that the agency demands scientific data, including toxicity and exposure, and conducts a rigorous review before allowing the use of the chemicals in contact with food are not accurate.

[/pullquote]Per- and poly-fluorinated alkyl substances (PFAS)—recently dubbed “forever chemicals”—have received a large amount of national attention, mostly due to contamination of drinking water affecting millions of Americans. Since June 2019, when the U.S. Food and Drug Administration (FDA) released its testing results from three studies, questions have arisen about food as a source of PFAS exposure. The main routes by which PFAS enter the food supply are environmental contamination—such as from nearby chemical manufacturing facilities, airports or Department of Defense operations—and from food packaging and processing equipment.

With greater attention on PFAS in food, we’ve noticed several misleading PFAS manufacturers’ talking points asserting that FDA review and acceptance is required for any PFAS to be used in contact with food, and that, due to this review, PFAS that go through this process are safe. However, their claims that the agency demands scientific data, including toxicity and exposure, and conducts a rigorous review before allowing the use of the chemicals in contact with food are not accurate.

Read More »

Posted in FDA, Food, GRAS, PFAS / Tagged , , | Read 1 Response

Chemours asks FDA to suspend its approved uses of PFAS in food packaging

By Tom Neltner, Senior Director, Safer Chemicals Initiative / Published: August 9, 2019

Tom Neltner, J.D., Chemicals Policy Director

Politico reported today that Chemours notified the Food and Drug Administration (FDA) that it had officially abandoned its three approved food packaging uses of per- and poly-fluorinated alkyl substances (PFAS) and asked the agency to withdraw its Food Contact Substance Notifications (FCNs) for those uses. We do not know with certainty what prompted Chemours to abandon its PFAS products for food packaging or whether they were ever used in the United States. Based on past experience, we anticipate that FDA will grant the request.

This action takes us one step closer to reducing people’s exposure to these chemicals linked to an array of health risks posed by PFAS at extremely low levels. Additionally, the action should serve as an incentive for other companies to do the same.

Chemours also has FCNs for six PFAS uses in repeat-use food contact articles like gaskets and seals. The company apparently has not asked the agency to abandon these uses. We suspect that the PFAS-treated gaskets may still be in service even if it has stopped treating new gaskets with the chemicals.

Read More »

Posted in FDA, Food, GRAS, Health science, PFAS / Tagged , , | Read 2 Responses